PubMed Health⌕ Search

Biomedical subjects

G Búzás

Publications and source records attributed to G Búzás.

9 recordsLinked to original sources
PubMed1985

Effect of ZnSO4 upon gastric acid secretion and carbonic anhydrase.

Starting from the multiple role zinc holds in the enzymatic processes of the body and from some positive data concerning treatment with zinc sulphate in gastric ulcer, we have studied the effect of ZnSO4 on gastric acid secretion in duodenal ulcer patients, as well as that on purified and gastric mucosa carbonic anhydrase. Gastric secretory testing showed that zinc sulphate administered in doses of 60 ml/day (1% solution) for 10 days reduced basal acid secretion in duodenal ulcer patients by 57.7%. In vitro, concentrations of ZnSO4 ranging between 10(-6) and 10(-2)M, inhibit purified carbonic anhydrase activity in a dose-dependent manner, reaching maximum effect at 10(-2)M, when carbonic anhydrase activity dropped from 2060 +/- 65 IU to 660 +/- 85 IU. A similar dose-dependent inhibition was found with gastric mucosa carbonic anhydrase activity, where ZnSO4 at 10(-2)M reduces enzyme activity from its basal value of 1.58 +/- 0.36 EU/mg to 0.88 +/- 0.21 EU/mg. Besides this effect, zinc sulphate antagonized in vitro the activation of both purified and gastric mucosa carbonic anhydrase by histamine. In conclusion, the mechanism of antisecretory effect of ZnSO4 might well be the inhibition of the carbonic anhydrase in the gastric mucosa.

Adult↗
PubMed1984

Effect of verapamil on purified bovine carbonic anhydrase. An in vitro study.

Relying on previous data which prove the activation of purified and gastric mucosa carbonic anhydrase by interaction of histamine with calcium ions, the present paper investigates the effect of verapamil, a specific antagonist of calcium transport, on purified bovine red cell carbonic anhydrase. In vitro determination of enzymatic activity according to Maren's micromethod showed that verapamil, in concentrations ranging from 10(-8)-10(-3) mol/l inhibits carbonic anhydrase basal activity in a dose-dependent manner. Thus, at 10(-3) mol/l verapamil concentration - representing its maximal effect - carbonic anhydrase basal activity drops from 2114 +/- 244 IU to 1100 +/- 86 IU (p less than 0.01). At this concentration, the drug antagonizes the activating effect of histamine: while maximum concentration (10(-2) mol/l) of histamine activates the enzyme from 2116 +/- 182 IU to 3979 +/- 411 IU the enzyme activity in the presence of verapamil changes in a non-significant way to 2162 +/- 148 IU (p less than 0.10). As calcium was omitted from the in vitro system, the mechanism described here is probably independent of ion transport inhibition. The physiologic importance of this effect for gastric secretion is to be further clarified.

Animals↗
PubMed1981

Inhibition of carbonic anhydrase by pirenzepine.

Previous work of the authors established a parallelism between gastric mucosa carbonic anhydrase (CA) activity and the values of acid secretion. It was shown that histamine (Ht) is a physiological activator of CA, and that there could be histaminic H2 receptors located on the molecule of CA. Pirenzepine (GZ) is a drug recently introduced in the therapy of gastroduodenal ulcer (GDU). Although its effect of decreasing acid secretion is clinically known, its mechanism of action remains uncertain. Original investigations are presented proving by in vitro and in vivo experiments on pure CA and on CA from human red blood cells and gastric mucosa that GZ is a strong inhibitor of CA. In this concept, GZ may be considered both an enzymatic inhibitor and an antagonist of histaminic H2 receptors.

Animals↗
PubMed1981

Inhibition of gastric mucosa carbonic anhydrase by pirenzepine in patients with gastroduodenal ulcers.

Pirenzepine (Gastrozepin) is a drug recently introduced in the therapy of gastroduodenal ulcer (GDU). Although its effect of decreasing acid secretion is clinically known, its mechanism of action remains uncertain. The authors present investigations proving by in vitro experiments carried out on pure carbonic anhydrase (CA) and on CA from human gastric mucosa that GZ is a strong inhibitor of CA. In this acceptation, GZ may be considered both an enzymatic inhibitor and an antagonist of histamine H2 receptors.

Animals↗
PubMedDate not supplied

"Ulcosilvanil"--an inhibitor of carbonic anhydrase--associated with adrenergic beta-blockers in the treatment of duodenal ulcers.

Knowing the in vivo inhibitory effect of the beta-adrenoreceptor antagonists on gastric mucosa carbonic anhydrase and the high clinical efficacy of "Ulcosilvanil" in the healing of gastric and duodenal ulcers, the authors combined propranolol with smaller doses of "Ulcosilvanil" in 925 active duodenal ulcer patients, divided into four groups. The first 236 patients were treated with small doses of "Ulcosilvanil" (20 mg/kg b.w./day active substance), the second group (of 258 cases) with high doses (35 mg/kg b.w./day) of "Ulcosilvanil", the third one (182 subjects) with propranolol only (60 mg/day) and the fourth group (349 patients) with small doses of "Ulcosilvanil" associated with 60 mg/day propranolol. Pain disappeared in all the cases of groups 1,2 and 4 after 3-6 days of treatment and in 40% of the third group. Basal acid output decreased, after 10 days of treatment, from 6.15 +/- 1.57 to 1.94 +/- 0.66 mEq/h in the first group (p less than 0.001), from 7.98 +/- 2.34 to 0.01 +/- 0.01 mEq/h in the second group (p less than 0.001), from 6.43 +/- 2.45 to 2.09 +/- 0.50 mEq/h in the third group (p less than 0.02) and from 6.76 +/- 2.80 to 0.011 +/- 0.01 mEq/h in the fourth group (p less than 0.001). Endoscopic healing was achieved, after 14 days of treatment, respectively in 78.5%, 92.4%, 51.6% and 88.41%; this percentages increased to 82.3%, 96.8%, 68.1% and 93.5% after 21 day of treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Acetazolamide↗